Genentech, Curis Win Approval Of Hedgehog Inhibitor Erivedge
Hedgehog has been a household name in biotech circles for decades – both because the Sonic Hedgehog protein owes its whimsical name to a Sega video game character and because scientists have long pursued ways to target the Hedgehog pathway. Now Roche AG's Genentech unit has succeeded – with a little help from Curis Inc. – winning FDA approval of Erivedge (vismodegib) for advanced basal cell carcinoma.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter